Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

simtuzumab

- PMLiVE

Two new hepatitis C therapies fast-tracked in Europe

EMA speeds review process for Gilead and AbbVie treatments

- PMLiVE

Ipsen buys cancer business from stripped down Merrimack

Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

- PMLiVE

Gilead files hepatitis C salvage regimen in US

Seeks FDA approval for combination of Epclusa and voxilaprevir

- PMLiVE

Torrid times at Gilead lead to calls for a major M&A deal

HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

- PMLiVE

Could Gilead face early Sovaldi generics in Europe?

EU patent protection for the hepatitis C virus drug will end in 2024

- PMLiVE

Allergan buys two NASH drug developers in one day

More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics

Gilead Sciences

Gilead’s Truvada cleared for HIV prevention in EU

May help slow down recent uptick in new HIV diagnoses

- PMLiVE

ViiV takes two-drug cocktail for first-line HIV into phase III

New approach hopes to reduce drug exposure and improve adherence

Gilead Sciences

Gilead’s hepatitis C sales start to slide – the question is how quickly?

CEO anticipates eventual “equilibrium” through shift toward treatment of less severely ill patients

- PMLiVE

Gilead’s universal hep C therapy Epclusa approved in EU

European nod for first pan-genotypic treatment follows recent FDA licensing

EU flag

European pharma ‘to grow 3.2% per year by 2022’

Forecast predicts AbbVie’s Humira will be knocked off the top spot

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links